Although there is a growing acceptance by regulatory agencies and commercial vaccine producers that improved vaccine adjuvants are needed to meet the infectious diseases, at present, the safety and regulatory hurdles that will be encountered with the addition of novel immunopotentiators and delivery systems to final vaccine formulations may be significant and are still largely ill defined.
1
—
—